Convalescent Plasma to Limit SARS-CoV-2 Associated Complications

Inclusion Criteria: * ≥ 18 years of age * Competent and capable to provide informed consent * • Positive molecular test for presence of SARS-CoV-2 in fluid collected by saliva for antigen, oropharyngeal or nasopharyngeal swab * Experiencing any symptoms of COVID-19 including but not limited to fever(T\> 100.5º F), cough, or other COVID associated symptoms like anosmia * ≤ 8 days since the first symptoms of COVID-19 * ≤ 8 days since first positive SARS-CoV-2 RNA test * Able and willing to comply with protocol requirements listed in the informed consent Exclusion Criteria: * Hospitalized or expected to be hospitalized within 24 hours of enrollment * Psychiatric or cognitive illness or recreational drug/alcohol use that in the opinion of the principal investigator, would affect subject safety and/or compliance * History of prior reactions to transfusion blood products * Inability to complete therapy with the study product within 24 hours after enrollment * Receiving any treatment drug for COVID-19 within 14 days prior to screening evaluation (monoclonal antibodies, compassionate use or study trial related). Steroid treatment at any time does not affect study eligibility